Inactive Instrument

News BioTime, Inc. Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 29	Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	CI
Mar. 11	Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	May. 02	BU
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE	May. 01	AQ
Lineage Cell Therapeutics : Immediate Report	Apr. 30	PU
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	Apr. 30	PU
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY	Apr. 30	PU
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)	Apr. 30	BU
Lineage Announces Changes to Board of Directors	Apr. 29	BU
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors	Apr. 29	CI
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	Apr. 01	BU
Lineage Cell Therapeutics : Immediate Report	Mar. 24	PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	Mar. 18	BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	Mar. 14	AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	Mar. 13	BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	BU
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting	Mar. 11	CI
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M	Mar. 10	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann	Mar. 10	PU
Lineage Cell Therapeutics : FORM S-3-Registration Statements	Mar. 10	PU
Lineage Cell Therapeutics : Annual report which provides a comprehensive overview of the company for the past year	Mar. 10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW